Please wait a minute...
European Journal of Gynaecological Oncology  2018, Vol. 39 Issue (2): 242-246    DOI: 10.12892/ejgo3879.2018
Original Research Previous articles | Next articles
The incidence and risk factors of severe neutropenia and febrile neutropenia due to chemotherapy among gynecologic cancer patients in Thailand
P. Pimsi1, 2, W. Santimaleeworagun2, *(), S. Therasakvichya3, N. Saengsukkasemsak4, A. Laocharoenkeat4
1 The College of Pharmacotherapy of Thailand, The Pharmacy Council of Thailand, Nonthaburi, Thailand
2 Department of Pharmacy, Faculty of Pharmacy, Silpakorn University, Nakhon Phathom, Thailand
3 Department of Obstetrics & Gynaecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
4 Department of Pharmacy, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
Download:  PDF(180KB)  ( 101 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Purpose: To investigate the incidence of chemotherapy-induced neutropenia and febrile neutropenia (FN) among patients with gynecologic cancer receiving initial chemotherapy and to determine associated risk factors related to neutropenia and FN. Materials and Methods: This retrospective study gathered the available record data of gynecologic cancer patients who received first-line chemotherapy from January 2012 to December 2015 at Siriraj Hospital,Thailand. All gynecologic cancer patients over the age of 18 and who had received initial chemotherapy were included. Results: Four hundred seven gynecologic cancer patients were included and there were 2,249 cycles of chemotherapy (17 regimens). Two hundred nine patients (52.0%) had severe neutropenia and 11 patients (2.7%) of 407 patients (2.7%) were diagnosed as FN. Carboplatin-containing regimens were the only one risk factor for severe neutropenia in the logistic analysis. Meanwhile, the use of myeloid growth factors for the prevention of FN could reduce the risk of FN (odd ratios 0.03; 95% confidence interval 0.005-0.231). Conclusion: The incidences of severe neutropenia and FN were 52.0% and 2.7%, respectively. It was also shown that myeloid growth factor use might act as a prevention among patient with intermediate risks of FN using cisplatin and doxorubicin.
Key words:  Febrile neutropenia      Severe neutropenia      Gynecologic cancer      Incidence      Risk factors     
Published:  10 April 2018     
*Corresponding Author(s):  W. SANTIMALEEWORAGUN     E-mail:  swichai1234@gmail.com

Cite this article: 

P. Pimsi, W. Santimaleeworagun, S. Therasakvichya, N. Saengsukkasemsak, A. Laocharoenkeat. The incidence and risk factors of severe neutropenia and febrile neutropenia due to chemotherapy among gynecologic cancer patients in Thailand. European Journal of Gynaecological Oncology, 2018, 39(2): 242-246.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo3879.2018     OR     https://ejgo.imrpress.com/EN/Y2018/V39/I2/242

[1] Katarzyna Plagens-Rotman, Piotr Merks, Grażyna Jarząbek-Bielecka, Małgorzata Mizgier. Does the consumption of pasta, rice and groats affect the risk of cancer of women’s reproductive organs and breast?[J]. European Journal of Gynaecological Oncology, 2021, 42(4): 655-661.
[2] Tomoko Sakamoto Taniguchi, Shinichi Komiyama, Masaru Nagashima, Mineto Morita. Characteristics of microsatellite instability-high gynecologic cancer and efficacy of pembrolizumab: a single-institution experience[J]. European Journal of Gynaecological Oncology, 2021, 42(4): 752-756.
[3] Xiao-Juan Wang, Ke-Qin Hua. Incidence and predictors of venous thromboembolism after surgery for gynecologic cancer[J]. European Journal of Gynaecological Oncology, 2021, 42(3): 477-481.
[4] Hacı Oztürk Şahin, Alpay Yilmaz, Mehmet Bayrak, Eren Pek, Kemal Özerkan, Hakan Ozan. Recurrence of borderline ovarian tumors: clinical and pathological risk factors[J]. European Journal of Gynaecological Oncology, 2021, 42(3): 580-586.
[5] Qihua Yi, Lin Chen, Sijing Chen, Ying Zheng. Criteria for predicting ovarian metastasis in early-stage cervical adenocarcinoma[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 726-731.
[6] Rie Nakamura, Yuko Shimoji, Tadaharu Nakasone, Yusuke Taira, Yoshihisa Arakaki, Tomoko Nakamoto, Keiko Mekaru, Wataru Kudaka, Tatsuya Kinjo, Yoichi Aoki. Malignant bowel obstruction in recurrent gynecologic cancers: who will benefit from palliative surgical intervention?[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 513-516.
[7] Lindsey Buckingham, Lori Cory, Colleen Brensinger, Xiaochen Zhang, Robert A. Burger, Fiona Simpkins, Emily M. Ko. Epidemiologic profile of benign versus oncologic gynecology populations: similar procedures, different patients[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 396-401.
[8] D. Kim, Y. Ki, W. Kim, D. Park, D. Suh, K. Kim, J. Lee, H. Jeon, J. Nam. Positive pelvic lymph node on [18F]-FDG PET is a prognostic factor in early-stage high-risk cervical cancer treated by radical hysterectomy and adjuvant chemoradiotherapy[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 42-47.
[9] T. Tantitamit, K.-G. Huang, A. Temtanakitpaisan. Emerging role of sentinel lymph node mapping for gynecologic oncology in the new era[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 905-914.
[10] C. Fang, J. Yang, W. Ding, K. Li, D. Weng, P. Wu, G. Chen, D. Ma, J. Wei. Incidence of symptomatic deep vein thrombosis after gynecological surgery: a retrospective study in Chinese population[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 939-942.
[11] I. Laskov, D. Grisaru, V. Deutsch, N. Fargo, Y. Raz, N. Mishaan. Evaluation of the hypercoagulable state of gynecologic cancer patients by thromboelastography: a prospective pilot study and a review of the literature[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 988-993.
[12] C. Cedolini, S. Bertozzi, A. P. Londero, I. Pradelle, S. Bernardi, V. Londero, A. Uzzau, M. Bazzocchi, C. Zuiani, A. Risaliti. Risk factors for breast cancer development in patients with borderline breast lesions: a retrospective analysis of our outpatient facility[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 572-578.
[13] L.D. Tasic, L.G. Antic, A.I. Jursic, S.D. Jankovic, B. Kastratovic Kotlica, N.T. Karadzov, D.Z. Antic. Creation of risk index for premalignant changes of the uterine cervix[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 464-469.
[14] Chunyu Xu, Chun Fang, Zhiguo Zhang, Jinwei Miao. Effects of community intervention on quality of life in women with gynecological cancers[J]. European Journal of Gynaecological Oncology, 2017, 38(6): 948-950.
[15] P.L. Tang, W.C. Huang, W.S. Liu, K.C. Chang. Analysis of gynecologic cancer patients visiting emergency department: a population-based cohort study in Taiwan[J]. European Journal of Gynaecological Oncology, 2017, 38(4): 522-528.
No Suggested Reading articles found!